bioRxivCancer BiologyPreprint
Loss of p53 tumor suppression function drives invasion and genomic instability in models of murine pancreatic cancer
Abstract
Pancreatic ductal adenocarcinoma (PDA) is a deadly disease with few treatment options. There is an urgent need to better understand the molecular mechanisms that drive disease progression, with the ultimate aim of identifying early detection markers and clinically actionable targets. To investigate the transcriptional and morphological changes associated with pancreatic cancer progression, we analyzed the KrasLSLG12D/+; Trp53LSLR172H/+; Pdx1-Cre (KPC) mouse model. We have identified an intermediate cellular event during pancreatic carcinogenesis in the KPC mouse model of PDA that is represented by a subpopulation of tumor cells that express KrasG12D, p53R172H and one allele of wild-type Trp53. In vivo, these cells represent a histological spectrum of pancreatic intraepithelial neoplasia (PanIN) and acinar-to-ductal metaplasia (ADM) and rarely proliferate. Following loss of wild-type p53, these precursor lesions undergo malignant de-differentiation and acquire invasive features. We have established matched organoid cultures of pre-invasive and invasive cells from murine PDA. Expression profiling of the organoids led to the identification of markers of the pre-invasive cancer cells in vivo and mechanisms of disease aggressiveness.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model
Isabel A. English, Patrick Joseph Worth, … Rosalie C. Sears·bioRxiv·Jul 14, 2025
- Drug-Induced p53 Activation Limits Pancreatic Cancer Initiation
Jennifer J. Twardowski, Thomas I. Heist, … Stephano S. Mello·bioRxiv·May 29, 2024
- Prevention and reversion of pancreatic tumorigenesis through a differentiation-based mechanism
N. M. Krah, D. Yugawa, … L. C. Murtaugh·bioRxiv·Nov 19, 2017
- Kras loss of heterozygosity promotes MAPK dependent pancreatic ductal adenocarcinoma and induces therapeutic sensitivity
S. K. Fey, A. K. Najumudeen, … O. J. Sansom·bioRxiv·Aug 29, 2023
- Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition
Jose Reyes, Isabella S. Del Priore, … Scott W. Lowe·CellPeer-reviewed·Apr 15, 2026
- Gα13 loss promotes tumor progression in the KPC transgenic mouse model of advanced pancreatic cancer
M. A. Shields, C. Spaulding, … H. G. Munshi·bioRxiv·Mar 15, 2021